Xiaoying Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaoying Jiang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Renren Bai
School of Pharmacy, Hangzhou Normal University
5 shared publications Hao Wen
School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, PR China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou 311121, PR China
2 shared publicationsHong Cai
School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, PR China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou 311121, PR China
2 shared publicationsJia Zhi
School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, PR China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou 311121, PR China
2 shared publicationsMeiling Feng
School of Pharmacy, Hangzhou Normal University
2 shared publicationsShan Wang
School of Pharmacy, Hangzhou Normal University
2 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 41 (1) , 2700840
Discovery of ALA-hydroxypyridinone hybrids: novel strategies for photodynamic therapy against superficial tumours
The treatment options for conventional tumours primarily encompass chemotherapy, radiotherapy, immunotherapy, and surgical intervention. In contrast, superficial tumours – including superficial ski...
- 8 July 2026
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 41 (1) , 2700840
Open AccessDiscovery of ALA-hydroxypyridinone hybrids: novel strategies for photodynamic therapy against superficial tumours
The treatment options for conventional tumours primarily encompass chemotherapy, radiotherapy, immunotherapy, and surgical intervention. In contrast, superficial tumours – including superficial ski...
- Open Access
- 28 December 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 87, 1079-1104
Strategy and efficiency-redefined discovery of novel nanomolar tyrosinase inhibitors: AI de novo molecular generation + expert-guided structural optimization
- 28 December 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 87, 1079-1104
Open AccessStrategy and efficiency-redefined discovery of novel nanomolar tyrosinase inhibitors: AI de novo molecular generation + expert-guided structural optimization
- Top Cited PapersOpen Access
Small-Molecule Tyrosinase Inhibitors for Treatment of Hyperpigmentation
Increasing attention is being focused on skin health currently, especially the excessive deposition of melanin in the skin. Tyrosinase, the rate-limiting enzyme in melanin biosynthesis, is a crucial enzyme in melanin synthesis. However, existing tyrosinase inhibitors pose some degree of toxicity to humans. Therefore, the development of more efficient and low-toxicity tyrosinase inhibitors is urgently needed. This review briefly depicts the melanin biosynthesis process and the crystal structure and catalytic mechanism of tyrosinase. The latest research progress regarding small-molecule tyrosinase inhibitors is also reviewed. Moreover, the structure–function relationships are analyzed and summarized. This is expected to provide new and more scientific insights to enable researchers to explore safer and more potent tyrosinase inhibitors.
Top Cited PapersOpen AccessSmall-Molecule Tyrosinase Inhibitors for Treatment of Hyperpigmentation
Increasing attention is being focused on skin health currently, especially the excessive deposition of melanin in the skin. Tyrosinase, the rate-limiting enzyme in melanin biosynthesis, is a crucial enzyme in melanin synthesis. However, existing tyrosinase inhibitors pose some degree of toxicity to humans. Therefore, the development of more efficient and low-toxicity tyrosinase inhibitors is urgently needed. This review briefly depicts the melanin biosynthesis process and the crystal structure and catalytic mechanism of tyrosinase. The latest research progress regarding small-molecule tyrosinase inhibitors is also reviewed. Moreover, the structure–function relationships are analyzed and summarized. This is expected to provide new and more scientific insights to enable researchers to explore safer and more potent tyrosinase inhibitors.
- 3 May 2024
- Published by Elsevier in Drug Discovery Today
- Vol. 29 (6) , 104013
Thyroid receptor β: A promising target for developing novel anti-androgenetic alopecia drugs
- 3 May 2024
- Published by Elsevier in Drug Discovery Today
- Vol. 29 (6) , 104013
Thyroid receptor β: A promising target for developing novel anti-androgenetic alopecia drugs
- 23 February 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 268, 116269
Small-molecule agents for treating skin diseases
- 23 February 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 268, 116269
Small-molecule agents for treating skin diseases